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A B S T R A C T
Hypophosphatasia (HPP) is a rare, inherited, systemic, metabolic disorder caused by autosomal recessive mu-
tations or a single dominant-negative mutation in the gene encoding tissue-nonspeciﬁc alkaline phosphatase
(TNSALP). The disease is associated with a broad range of signs, symptoms, and complications, including im-
paired skeletal mineralization, altered calcium and phosphate metabolism, recurrent fractures, pain, respiratory
problems, impaired growth and mobility, premature tooth loss, developmental delay, and seizures. Asfotase alfa
is a human, recombinant enzyme replacement therapy that is approved in many countries for the treatment of
patients with HPP. To address the unmet need for guidance in the monitoring of patients receiving asfotase alfa,
an international panel of physicians with experience in diagnosing and managing HPP convened in May 2016 to
discuss treatment monitoring parameters. The panel discussions focused on recommendations for assessing and
monitoring patients after the decision to treat with asfotase alfa had been made and did not include re-
commendations for whom to treat. Based on the consensus of panel members, this review provides guidance on
the monitoring of patients with HPP during treatment with asfotase alfa, including recommendations for la-
boratory, eﬃcacy, and safety assessments and the frequency with which these should be performed during the
course of treatment. Recommended assessments are based on patient age and include regular monitoring of
biochemistry, skeletal radiographs, respiratory function, growth, pain, mobility and motor function, and quality
of life. Because of the systemic presentation of HPP, a coordinated, multidisciplinary, team-based, patient-fo-
cused approach is recommended in the management of patients receiving asfotase alfa. Monitoring of eﬃcacy
and safety outcomes must be tailored to the individual patient, depending on medical history, clinical mani-
festations, availability of resources in the clinical setting, and the clinician's professional judgment.
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1. Introduction
Hypophosphatasia (HPP) is a rare, inherited, systemic, metabolic
disorder that is sometimes life-threatening in infants and can lead to
disability at any age. HPP is characterized by low activity of the enzyme
tissue-nonspeciﬁc alkaline phosphatase (TNSALP), resulting in a broad
range of signs, symptoms, and complications [1,2]. Deﬁcient TNSALP
activity in HPP is caused by autosomal recessive mutations or a single
putative dominant-negative mutation in the liver/bone/kidney alkaline
phosphatase (ALP) gene (ALPL) encoding TNSALP [3,4] and leads to
extracellular accumulation of TNSALP substrates, chieﬂy inorganic
pyrophosphate (PPi; an inhibitor of hydroxyapatite crystal formation
and bone mineralization) [2,5,6] and pyridoxal-5′-phosphate (PLP; the
circulating form of vitamin B6, which without TNSALP activity is
thought to fail to cross the blood-brain barrier, as well as cell mem-
branes) [2,7,8]. Phosphoethanolamine (PEA; a degradation product of
cell surface phosphatidylinositol-glycan anchors) is also a substrate,
although not exclusively, of TNSALP in vitro [9–11].
Depending on the patient's age, the signs, symptoms, and compli-
cations of HPP can include bone anomalies detected in utero, premature
tooth loss (exfoliation of the entire tooth including root), impaired
skeletal mineralization, bone deformities, fractures, bone/joint/muscle
pain, respiratory compromise that may require ventilation, impaired
growth and mobility, vitamin B6-dependent seizures, craniosynostosis,
substantial morbidity, and, in some cases, death [2,12,13].
The clinical presentation of HPP is possibly inﬂuenced by autosomal
dominant versus autosomal recessive inheritance [14,15], as well as
environmental and epigenetic factors and modiﬁer genes [16]. HPP has
been clinically classiﬁed according to age at ﬁrst sign or symptom
onset: perinatal (in utero and at birth), infantile (age < 6 months),
childhood (age≥ 6 months to< 18 years), and adult (age≥ 18 years)
[1,2,15,17]. HPP presenting primarily with dental manifestations has
been described as odontohypophosphatasia [18–20]. Skeletal manifes-
tations of HPP in utero have been observed, which in some cases may
resolve spontaneously after birth; this has been described as benign
prenatal HPP [21,22]. These categories are helpful in describing the
disease; however, the clinical presentation of HPP is variable [23] and
the disease burden throughout an individual patient's life is not well
understood [12,14,24]. Substantial morbidities may develop during the
lifetime of a patient with HPP [25], who may have increasing disease
burden resulting from joint problems, fractures, orthopedic/dental
surgeries, pain, muscular insuﬃciency, decreased functional status, and
impaired mobility [1,25,26].
Until recently, treatment of HPP consisted largely of supportive care
[2]. Use of bisphosphonates has not been rigorously studied in patients
with HPP [27]; in case studies of adults with previously undiagnosed
HPP, treatment with bisphosphonates potentially led to an increase in
and/or worsening of fractures [28,29]. Teriparatide (recombinant
human parathyroid hormone [PTH] 1–34) has shown some beneﬁt in
case studies of adults with HPP [30,31], although one case report de-
scribed no beneﬁt [32]. Teriparatide is contraindicated in pediatric and
young adult patients with open epiphyses; studies in rats showed an
increase in the incidence of osteosarcoma that was dose and treatment
duration dependent [27,33]. Teriparatide is currently not re-
commended for use in the treatment of osteoporosis for longer than
2 years over a lifetime [33]. Case reports for other approaches, such as
bone marrow and stem cell transplantation, in infants and children with
HPP have described some improvement in skeletal mineralization and
survival to at least age 3 to 7 years in patients with life-threatening
disease; however, the improvement in skeletal mineralization was not
necessarily associated with an improvement in ALP activity [34–36].
Asfotase alfa (Strensiq®; Alexion Pharmaceuticals, Inc., New Haven,
CT, USA), a human, recombinant TNSALP replacement therapy, re-
places deﬁcient TNSALP activity in patients with HPP and reduces the
accumulation of extracellular TNSALP substrates [37]. The eﬃcacy and
safety of asfotase alfa was assessed in 5 prospective, open-label, Phase
2, multinational clinical studies in infants and adolescents with peri-
natal, infantile, or childhood HPP [37–40]. In these studies, asfotase
alfa improved bone mineralization based on radiographic and biopsy
ﬁndings and improved growth, respiratory function, and mobility. A
study of asfotase alfa in adolescents and adults with HPP has been
completed, and the results are being prepared for publication.
No published guidelines are available for monitoring patients with
HPP being treated with asfotase alfa. To address this unmet need, in
May 2016, Alexion Pharmaceuticals, Inc., convened an international
panel of physicians to discuss treatment monitoring parameters for
patients with HPP who are receiving asfotase alfa. For this discussion, it
was presumed that the decision to treat with asfotase alfa had already
been made; other possible therapeutic approaches, symptom manage-
ment with other treatments, and general management of HPP were not
discussed and are beyond the scope of this report. It should also be
noted that access to and experience with this drug currently vary from
country to country. Further, the decision to discontinue treatment is
complex and also beyond the scope of this paper; the decision is mul-
tifactorial and should be considered using a case-by-case approach
based on discussions and understanding between the patient, family,
and physicians. The intention of this consensus report is to provide
guidance on the monitoring of patients with HPP receiving treatment
with asfotase alfa, including clinical recommendations concerning la-
boratory, eﬃcacy, and safety assessments and the frequency with which
these should be performed during the course of treatment.
1.1. Methodology
All physicians involved in the panel discussions were experienced in
the management of HPP. Their areas of expertise included pediatrics,
metabolic bone disease, endocrinology, gastroenterology, genetics,
clinical biochemistry, and orthopedic surgery. After the meeting, nurses
experienced in administering asfotase alfa were consulted to obtain
feedback on their recommendations for injection technique.
During the meeting, panel members reached consensus on the
monitoring of infants, children, and adults with HPP treated with as-
fotase alfa and prioritized the importance of assessments for each age
group. Evidence from the asfotase alfa clinical studies was used where
available and appropriate to guide recommendations. A comprehensive
review of the literature was undertaken to establish the foundation for
diagnosis and genetic testing for HPP. All authors reviewed and unan-
imously approved these recommendations.
Although these recommendations provide a basic framework, the
signs, symptoms, and complications of HPP vary widely from patient to
patient. Thus, treatment and monitoring ultimately should be tailored
to the patient based on the individual's medical history, clinical mani-
festations, and the clinician's professional judgment.
1.2. Diagnosis
Considerations for the diagnosis of HPP have been reviewed in other
publications [1,12] and were not a primary focus of the panel discus-
sions. Brieﬂy, the diagnosis of HPP in patients of any age can be es-
tablished based on characteristic signs, symptoms, and complications of
HPP (Table 1) [1,2,9,13,26,39,41–52] in combination with consistently
low age- and sex-adjusted serum ALP activity [1,13] after exclusion of
other causes of low ALP activity and skeletal diseases with similar
presentations [2]. Because the lower limit of normal for ALP activity
varies by age and sex [53], measured activity must be compared with
the lower limit and range appropriate for the patient [13]. Physicians
should be aware that many institutions do not routinely ﬂag low ALP
activity [2] and may incorrectly use adult ALP reference ranges and
apply them to patients of all ages. It should be emphasized that age- and
sex-adjusted ALP reference intervals are critical to making an accurate
diagnosis of HPP. Obtaining activity of the bone isoform of ALP is
generally not necessary or helpful, although it too would be expected to
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be low compared with age- and sex-adjusted reference intervals. Ad-
ditionally, elevated concentrations of ALP substrates, including plasma
PPi, plasma PLP, and urine PEA, may help support the diagnosis for all
age groups [2,24,54], although elevation of natural substrates may vary
by patient [55–58].
1.3. Genetic testing
More than 330 distinct mutations in the ALPL gene encoding the
TNSALP enzyme in HPP have been identiﬁed [4,59,60]. Genetic testing
for TNSALP mutations is helpful as a conﬁrmatory tool in cases of di-
agnostic uncertainty, to counsel the family on the risk of inheritance for
other family members, and to advance understanding of the disease
[61]. Involvement of a clinical geneticist in the interpretation of these
results is warranted. The recommended initial test is ALPL-gene se-
quencing, and if results are normal, it is recommended to proceed to
deletion/duplication analysis. In clinical practice, it is common to order
both simultaneously, with instructions to “reﬂex” to deletion/duplica-
tion of sequencing to improve convenience for the patient and ordering
provider. Sequencing of the ALPL gene by Sanger sequencing or next
generation sequencing should include all exons and should extend into
splice site regions. To date, this allows for detection of approximately
95% of the known ALPL mutations [59,60]. Multigene panels that in-
clude ALPL may also be used, particularly in cases of diagnostic un-
certainty. Ordering clinicians should be aware of the depth of coverage
when using next generation sequencing technology or whole-exome
sequencing, as low coverage regions may harbor pathogenic variants
that are not detected. Recommendations for genetic testing will change
as research advances.
2. Multidisciplinary management of patients with HPP
Given the heterogeneity of HPP, patients may present to a number
of diﬀerent healthcare professionals. A coordinated, team-based ap-
proach is essential to the eﬀective management of a patient with this
disease, regardless of chosen therapy or management approach. The
multidisciplinary team should include an individual who will serve as
coordinator of care in charge of managing the disease and a core care
team (Fig. 1). The core care team would be frequently engaged in
managing various aspects of patient care and change as the patient
ages, whereas specialists would vary more by presentation. For infants
and children with HPP, it is recommended that the core care team in-
clude an endocrinologist, medical geneticist, pediatrician, or other
healthcare professional specializing in pediatric metabolic bone dis-
orders to be responsible for coordinating care and overseeing the
challenges of managing patients with HPP. As children with HPP be-
come adults and require diﬀerent services, new treatment teams with
expertise in musculoskeletal disorders/disabilities and metabolic dis-
eases will need to be established. Coordination of care may vary by
country, region, center, and available resources. Dentists, nurses and
allied health professionals (e.g., social workers, genetic counselors,
physical therapists, occupational therapists) experienced in HPP may
also play an important role in patient education and family support.
3. Treatment goals
The goals of treatment with asfotase alfa in patients with HPP are
presented in Table 2 and focus on attainment of good health and
function. For perinatal/infantile patients, goals include survival, im-
proved ventilatory status, control of seizures, and discharge from hos-
pital. Treatment of infants and children with HPP has similar goals,
such as improved growth and mobility (depending on initial clinical
presentation), improved neurologic development, and improved mi-
neralization of bone. For adult patients with fractures, treatment goals
include reduced number and frequency of fractures, particularly
pseudo-fractures and insuﬃciency fractures, and improved fracture
healing; it is also important to avoid treatments that could cause further
clinical deterioration (e.g., bisphosphonates). In adults with and
without fractures, goals include improved functional status as measured
by strength, endurance, and improvements in gait. Reducing fatigue is
also an important treatment goal, given that fatigue may be a con-
siderable cause of morbidity in adults with HPP. Important goals for all
patients include oral health, attainment of developmental milestones,
improvements in mobility, reduced pain, and improved quality of life
(QOL).
4. Monitoring recommendations
Members of the advisory panel reached consensus on re-
commendations for laboratory, eﬃcacy, and safety assessments and
Table 1
Clinical, biochemical, and radiologic features of HPPa [1,2,9,13,26,39,41–52].
Perinatal/infantile (In utero to< 6 months of age) Childhood (≥6 months to 18 years of age) Adult (≥18 years of age)
• Stillbirth• Respiratory failure or insuﬃciency requiring support• Severe chest deformity (rachitic chest, gracile ribs, rib
fractures, narrow thoracic inlet)
• Severe skeletal hypomineralization or
undermineralization
• Osteochondral spurs• Rachitic-like lesions• Metaphyseal radiolucencies• Bowing deformities with or without fractures• Limb shortening• Muscle weakness with hypotonia• Intracranial hemorrhages• Seizures (vitamin B6 dependent)• Craniosynostosis leading to raised intracranial pressure• Hearing loss• Failure to thrive• Hypercalciuria• Nephrocalcinosis• Ophthalmic calciﬁcations• Premature deciduous tooth loss
• Poor bone mineralization• Bowing deformity• Rachitic-like lesions• Metaphyseal radiolucencies• Fractures• Delayed walking• Waddling gait• Muscle weakness• Missed motor milestones• Pain and stiﬀness• Short stature• Craniosynostosis leading to raised
intracranial pressure
• Hearing loss• Failure to thrive• Hypercalciuria• Nephrocalcinosis• Ophthalmic calciﬁcations• Premature loss of teeth with intact roots/
lack of cementum
• Poorly healing or recurrent fractures (metatarsal stress,
subtrochanteric femoral pseudo-fractures)
• Joint dislocation• Chronic muscle or bone pain• Muscle weakness• Fatigue• Immobility• Osteoarthropathy• Osteomalacia• Pseudogout/calcium pyrophosphate deposition disease/
crystal arthropathy
• Chondrocalcinosis• Nephrocalcinosis• Risk for ophthalmic calciﬁcations• Adult tooth loss• Abnormal dentition, including discoloration, excessive
dental caries, use of bridges/loose teeth
• Premature loss of teeth with intact roots/lack of cementum
HPP, hypophosphatasia.
a These categories are helpful in describing the disease; however, the clinical presentation of HPP is variable and the disease burden throughout an individual patient's life is not well
understood.
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their frequency in the monitoring of patients with HPP who are treated
with asfotase alfa. Recommendations vary by age group and are sum-
marized below for infants, children, and adults with HPP.
4.1. Laboratory testing
Recommendations for laboratory monitoring are summarized for all
age groups in Table 3. Measurement of ALP activity (adjusted for age
and sex) is critical for the diagnosis of HPP and is an essential minimum
baseline assessment for all patients treated with asfotase alfa. After
treatment initiation, monitoring ALP activity may be useful in discus-
sions about medication compliance with patients, parents, or caregivers
and potentially provide insights on immune responses (e.g., if a patient
has continued increases in ALP activity but no clinical improvement,
this could be because of neutralizing antibodies).
At this time, laboratory testing for PPi is not commercially available
and has been performed only in the research setting [2]; the availability
of this assay may increase in the future. Concentrations of plasma PLP
may be assessed by measuring vitamin B6, and urinary PEA can be
measured using commercially available tests, such as urine amino acids.
Assay consistency should be considered when interpreting bio-
chemical test results (e.g., fasting conditions in children and adults,
discontinuing supplements 1 week before testing, if possible). As ex-
pected, in clinical studies, administration of asfotase alfa resulted in
measurements of serum ALP activity above the normal range (up to
several thousand units per liter). Substrates of TNSALP (PPi, PLP, and
PEA) are commonly high in patients with HPP and are often used to
support diagnosis. However, it is not unusual for concentrations of PPi
and PLP to be undetectable in patients treated with asfotase alfa as an
artifact of asfotase alfa continuing to hydrolyze substrates in blood
collection tubes during processing. To accurately measure PPi and PLP
concentrations, an ALP inhibitor, such as levamisole, would need to be
added to blood samples to inhibit in vitro degradation of PPi and PLP to
allow for correct interpretation of the results and to guide treatment.
Asfotase alfa may interact with enzyme-linked immunosorbent as-
says (ELISAs) that use ALP as the enzyme conjugate for quantiﬁcation.
Depending on the design of the ELISA, the presence of asfotase alfa may
cause false lows in some tests and false highs in others. Because of this
potential for interference, use of assays that do not include an ALP
conjugate is recommended for patients treated with asfotase alfa.
Laboratories and clinicians are encouraged to liaise closely with their
clinical chemist or pathology department if a patient receiving treat-
ment with asfotase alfa has laboratory test results that seem unusual.
4.2. Perinatal and infantile patients
Perinatal and infantile patients with HPP are very fragile and
usually require treatment in an intensive care setting. A schedule of
assessments recommended for monitoring perinatal and infantile pa-
tients is summarized in Table 4. Radiographs reviewed by a radiologist
familiar with HPP are critical for diagnosis and monitoring response to
treatment in these patients. At baseline, a comprehensive skeletal
survey should be performed. Some patients may show skeletal im-
provement as early as 1 month after treatment initiation; however, the
panel's consensus was to obtain radiographs of the chest, wrists, and
knees 3, 6, and 12 months after initiating asfotase alfa, except when
disease severity warrants more frequent imaging. Radiographic ﬁndings
after 6 months of treatment can help guide decisions regarding dose
adjustments; more frequent radiographic assessments should be limited
to minimize radiation exposure, unless clinically indicated. Baseline
respiratory assessments and age-appropriate pulmonary function
testing are recommended, with more frequent monitoring and/or re-
spiratory consults based on individual patient symptoms. Even a patient
who is oﬀ a ventilator may experience persistent respiratory compro-
mise.
Growth parameters should be routinely monitored and include
length/height, weight, body mass index, and head circumference and
shape (failure of the skull to grow can indicate craniosynostosis); on
treatment, these parameters may be maintained, increase, or in some
cases, exceed percentile lines. Routine monitoring of gross and ﬁne
motor function by a physical therapist and occupational therapist is
recommended for patients of all ages. Baseline and follow-up assess-
ments of pain and QOL are also important but diﬃcult to assess in
perinatal and infantile patients because no HPP-speciﬁc tool exists to
evaluate these parameters. Until such tools become available, the
Neonatal Infant Pain Scale [65,68] may be used to monitor pain and the
PedsQL (Pediatric Quality of Life Inventory) Infant Scales [66] may be
used to monitor QOL.
4.3. Children
A schedule of recommended assessments for monitoring children
Table 2
Treatment goals for patients with HPP treated with asfotase alfa.
Perinatal/infantile (in utero to< 6 months of age) Childhood (≥6 months to 18 years of age) Adult (≥18 years of age)
• Survival• Improved respiratory status (ventilatory
support)
• Skeletal improvements• Metabolic control, prevention of renal failure• Improved growth and physical development
(e.g., weight gain)
• Meet developmental milestones• Treat craniosynostosis• Seizure control• Hospital discharge• Pain reduction• Oral health• Improved quality of life
• Improved mobility• Skeletal improvements• Radiographic improvements (reduced tongues of
radiolucency)
• Improved growth• Meet developmental milestones• Nephrocalcinosis prevention• Pain reduction• Oral health• Improved quality of life
• Patients with fractures
– Improved fracture healing
– Reduced fracture frequency
– Reduced number/prevention of pseudo-fractures and
insuﬃciency fractures
– Avoidance of treatments that could cause further clinical
deterioration (e.g., bisphosphonates)
• Patients with and without fracturesa
– Improved functional status
- Endurance
- Strength
- Gait/walking
– Reduced fatigue
– Reduced dislocations
– Improved joint issues
– Reduced joint pain
– Improved bone quality
– Pain reduction
– Oral health
– Improved quality of life
HPP, hypophosphatasia.
a Patients may have residual complications owing to past fractures.
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with HPP is summarized in Table 5. Given the variability of clinical
manifestations in children and the wide age range of patients (6 months
to< 18 years), the panel divided the group by age and discussed dif-
ferences in treatment monitoring for younger (6 months to< 5 years at
ﬁrst signs or symptoms) versus older (≥5 to< 18 years at ﬁrst signs or
symptoms) children. At baseline, respiratory assessments and pul-
monary function testing are important for both younger and older
children; more frequent monitoring and/or respiratory consults may be
considered based on individual patient symptoms. If sleep studies show
sleep disordered breathing, assessment by an ear, nose, and throat
specialist and/or pulmonologist may be necessary [69]. Dental assess-
ments are important after teeth have erupted. Baseline assessment of
bone mineral density (BMD) using dual-energy X-ray absorptiometry
(DXA; height-adjusted lumbar spine and total body) may be useful (see
Adults section), although use of DXA in HPP patients can be confounded
by aberrant density readings, which the panel speculated may be a
result of increased proteinaceous components of nonmineralized bones;
its use warrants further research. Further recommendations on the use
Table 3
Laboratory assessments in patients with HPP treated with asfotase alfa.
Laboratory test Frequency Special considerations
ALP activity • Perinatal/infantile: Baseline, 3, 6, and 12 months, and then every
6 months
• Childhood and adult: Baseline, 2 weeks, 3, 6, and 12 months, and
then annually
• Critical for diagnosis• Ensure that testing lab uses age- and sex-adjusted reference ranges• Signiﬁcant changes may require further investigation• May be useful in assessing compliance• Note on test request form that the sample should be diluted if possible
to get an accurate reading
Plasma PLP • Perinatal/infantile: Baseline, 1, 3, 6, and 12 months, and then
annually
• Childhood and adult: Baseline, 3 months, and then annually
• Active form of vitamin B6• Vitamin B6 supplements can confound results• Current issues with testing while on asfotase alfa owing to
degradation in vial would necessitate addition of an ALP inhibitor,
such as levamisole, to the vial for results to be interpretable
Plasma PPi • PPi levels were measured in the clinical trial program for asfotase
alfa. Reductions were observed within 6–12 weeks of treatment;
however, reductions were not correlated with clinical outcomes.
The clinical utility of this assessment has not been explored in the
real-world setting
• Not commercially available
Urine PEA • Perinatal/infantile: Baseline, 1, 3, 6, and 12 months, and then
annually
• Childhood and adult: Baseline, 3 months, and then annually
• Can support diagnosis
Calcium • Perinatal/infantile: Baseline, 1, 3, 6, and 12 months, then annually;
monitor as needed in the acute hypercalcemic until controlled
• Childhood and adult: Baseline, 3 months, and then annually
• Serum calcium should be adjusted for albumin• Ionized calcium (preferred, most consistent)• Hypercalcemia may be evident at diagnosis• Hypocalcemia may occur on treatment; supplementation may be
needed when on asfotase alfa
• Assess more frequently if patient is not improving on treatment• Calcium abnormalities are rare in adults, but may be in the upper
limits of the reference range
• Can be done locally and can be available at appointments
PTH • Baseline and then periodically based on calcium metabolism in
individual patient
• For detecting alterations in bone/mineral metabolism• Related to long-term calcium levels• Perform if calcium levels present an issue• Can be done locally and can be available at appointments
Vitamin D (25-
hydroxyvitamin D)
• Perinatal/infantile: Baseline, 1, 3, 6, and 12 months, and then
annually once normal levels reached
• Childhood and adult: Baseline, 3, 6, and 12 months, and then
annually once normal levels reached
• For ruling out additional cause of deﬁcient mineralization• Ensure vitamin D suﬃciency during treatment• Patients with conﬁrmed deﬁciency should receive supplementation
and be reassessed periodically
• Can be done locally and can be available at appointments
PO4 • Perinatal/infantile: Baseline, 1, 3, 6, and 12 months, and then
annually
• Childhood and adult: Baseline, 3 months, and then annually
• Monitor for serum phosphate (In clinical trials, initial changes in
serum phosphate levels were variable in response to treatment, with
some patients experiencing an increase and some a decrease, but the
values normalized with continued treatment. Some decreases in
serum phosphate levels appeared to coincide with decreases in
serum calcium during the ﬁrst several weeks of treatment, likely
due to increased skeletal mineralization)
• Assess more frequently if patient is not improving on treatment• Can be done locally and can be available at appointments
Routine blood tests • Perinatal/infantile: Baseline, 3, 6, 9, and 12 months, and then
annually
– Monitor closely during acute phase until stable
• Childhood and adult: Baseline, 6 months, and then annually
• Complete blood count• Liver function (bilirubin, ALT, AST)• Electrolytes
Classic renal panel • Perinatal/infantile: Baseline and every 3 months
– Monitor closely during acute phase until stable
• Childhood and adult: Baseline, 6 months, and then annually
• Creatinine, BUN• eGFR (adults)• Urine Ca/Cr (monitor for nephrocalcinosis)
ADA (anti-asfotase alfa IgG) • All groups: As clinically indicated and available • Not commercially available• Currently available for research use only and through the HPP
Registry (www.hppregistry.com)
• Ideally, test will include information on whether ADA are neutralizing• Interpretation of results and impact on patient management remain to
be determined
ADA, antidrug antibodies; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Ca/Cr, calcium/creatinine ratio; eGFR,
estimated glomerular ﬁltration rate; HPP, hypophosphatasia; IgG, immunoglobulin G; PEA, phosphoethanolamine; PLP, pyridoxal-5′-phosphate; PPi, inorganic pyrophosphate; PTH,
parathyroid hormone.
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Table 4
Monitoring recommendations for perinatal/infantile patients with HPP treated with asfotase alfa.
Assessment Frequency Special considerations
Radiograph Baseline, 3, 6, and 12 months, and then annually for wrists and every
2 years for knees, or as clinically indicated
• Critical for diagnosis• Comprehensive skeletal surveya• Radiographs of knees, wrists, and chest used to monitor treatment• Consider dose adjustment after 6 months on treatment with no improvement and if no
other causes of drug failure identiﬁed
• Study data support 3 months on assessment schedule
Respiratory Baseline and then as clinically indicated • Extremely important assessment/consultation for this age group• Mode of ventilation: Room air O2 saturation, noninvasive ventilation, CPAP, BiPAP,
ventilator, tracheostomy
• Sleep study before discharge and per pulmonary consultation until normal• Pulmonary consultation before air ﬂight—consider hypoxia altitude simulation test
Growth Baseline, every 3 months until age 4, and then every 6 months • Length (before 2 years), height (after 2 years), weight, and head circumference• Should be performed routinely by primary care physician
Motor function Baseline, 3, 6 and 12 months, and then annually • To be performed by PT/OT (BSID-III recommended [62])• AIMS [63] and GMFM [64] can also be used• Gauge changes through informal discussions during appointments
Pain Baseline, every month for the ﬁrst 6 months, and then every 3 months • Monitor with every visit• Consider a tool such as NIPS [65]
QOL Baseline and then annually • May be challenging to assess; consider a tool such as the PedsQL Infant Scales [66]
or EQ-5D-5L (2-page survey for parents) [67]
Safety See Table 8
AIMS, Alberta Infant Motor Scale; BiPAP, bilevel positive airway pressure; BSID-III, Bayley Scales of Infant and Toddler Development, Third Edition; CPAP, continuous positive airway
pressure; EQ-5D-5L, EuroQol 5-dimension 5-level health questionnaire; GMFM, Gross Motor Function Measure; HPP, hypophosphatasia; NIPS, Neonatal Infant Pain Scale; OT, occu-
pational therapist; PedsQL, Pediatric Quality of Life Inventory; PT, physical therapist; QOL, quality of life.
a Anteroposterior projections of the left wrist can be used to monitor epiphyses involvement and bone age in pediatric through adolescent HPP patients and may be obtained annually.
A skeletal survey for HPP may additionally include anteroposterior projections of feet (focus metatarsals), tibia/ﬁbula and femur (include femoral head), chest, spine (include lateral), and
skull (include lateral). With growth and closing of epiphyses, ﬁlms focused more on known problem areas in a speciﬁc individual are more useful than a complete survey. Screening for
potential progression or general complication (e.g., kyphoscoliosis, chondrocalcinosis, bone mineral loss) or age-dependent complications (e.g., craniosynostosis in children, occult
metatarsal stress fractures in adults) should ensue as patients get older.
Table 5
Monitoring recommendations for children with HPP treated with asfotase alfa.
Assessment Frequency Special considerations
Radiograph Baseline, 6 and 12 months, and then annually for wrists and
every 2 years for knees, or as clinically indicated
• Comprehensive skeletal survey at diagnosis as appropriate• Bilateral wrist/knee for monitoring treatment• Use of RSS is recommended to follow improvement of rachitic changes
DXA At physician's discretion; at least every 2 years • Normalized data are not available for children aged< 3 years, but absolute BMD values
can be used to measure change over time
Respiratory Baseline and then as clinically indicated • ENT assessment for older children (aged ≥5 years at ﬁrst symptoms) for concerns
regarding upper airway obstruction
• Pulmonary function test for concerns regarding lower airway or pulmonary function• Level of respiratory support important at baseline• Annually in patients with bronchomalacia or laryngomalacia
Dental Baseline; normal dental care • Only after teeth have erupted
Growth Baseline, every 3 months until age 4, and then every
6 months
• Length, height, weight, and head circumference• Should be performed routinely by primary care physician
Motor milestones Routine baseline, and then every 6 months • To be performed by PT/OT (BSID-III [62] or PDMS-2 [71] recommended, based on age)
Mobility Baseline, 3 months, and then once a year • 6MWT (for ambulatory children aged ≥5 years) [72]• AIMS [63] and GMFM [64] are recommended for younger children• If available, record video for comparisons over time
Gait Baseline, 6 and 12 months, and then annually • Additional assessments may be added based on 12-month results
Muscle strength Baseline, 6 and 12 months, and then annually • Dynamometer if available; grip and pinch strength
Pain Baseline, 6 and 12 months, and then annually • Tools such as CHAQ [73] and PODCI [74] may be considered• Recommended more frequently beyond 12 months if initial assessment identiﬁes need for
follow-up (i.e., patients with minimal pain do not require further testing)
QOL Baseline, 6 months, and then annually • HPP-speciﬁc scale is desired
GI Baseline, 6 and 12 months, and then annually • Monitoring for gastroesophageal reﬂux and aspiration (recurrent choking, pneumonia)
Nutrition Baseline and then annually • Nutritional assessment, including calcium intake in diet, vitamin use, and vitamin D3
Safety See Table 8
6MWT, 6-Minute Walk Test; AIMS, Alberta Infant Motor Scale; BMD, bone mineral density; BSID-III, Bayley Scales of Infant and Toddler Development, Third Edition; CHAQ, Childhood
Health Assessment Questionnaire; DXA, dual-energy X-ray absorptiometry; ENT, ear, nose, and throat specialist; GI, gastrointestinal; GMFM, Gross Motor Function Measure; HPP,
hypophosphatasia; OT, occupational therapist; PDMS-2, Peabody Developmental Motor Scales, Second Edition; PODCI, Pediatric Outcomes Data Collection Instrument; PT, physical
therapist; QOL, quality of life; RSS, Rickets Severity Scale.
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of DXA in children are provided by the International Society for Clinical
Densitometry [70].
Mobility may be diﬃcult to assess in young children. The Alberta
Infant Motor Scale [63] and Gross Motor Function Measure [64] are
recommended for younger children. For ambulatory children aged
≥5 years, baseline and follow-up assessments of mobility using the 6-
Minute Walk Test (6MWT) [72], performed by an experienced physical
therapist in accordance with American Thoracic Society guidelines
[75], are recommended. When possible, the 6MWT may be recorded on
video to allow comparison of gait and mobility over time. Based on the
patient's age, the Bayley Scales of Infant and Toddler Development,
Third Edition (age≤42 months) [62], and the Peabody Developmental
Motor Scales, Second Edition (birth through age 5 years) [71], are
helpful for monitoring motor milestones in children.
Pain and QOL are important to assess periodically throughout a
patient's treatment. Changes in analgesic medication and dosage can be
monitored to identify possible changes in pain levels. Pain may be as-
sessed using the Childhood Health Assessment Questionnaire [73] and
the Pediatric Outcomes Data Collection Instrument [74]. QOL assess-
ments become more important and more straightforward in older
compared with younger children. The PedsQL [76] may be helpful for
monitoring QOL; however, there is still a need for an HPP-speciﬁc QOL
scale.
4.4. Adults
Monitoring recommendations for adults are summarized in Table 6.
Depending on clinical presentation, prevailing symptoms, and national/
regional medical practice, a full skeletal survey of adults can be com-
pleted at baseline. Bone biopsy can be considered, particularly for pa-
tients with additional skeletal risk factors beyond HPP, such as chronic
kidney disease, history of fractures, or very low BMD. Re-evaluation
during treatment can help determine if bone quality and structure are
improved by enzyme replacement therapy. Although BMD variations
during treatment have not been systematically assessed in HPP patients,
DXA may be considered before treatment to assess fracture risk and
detect changes during treatment. However, DXA results should be in-
terpreted with caution, as HPP bone characteristics might aﬀect ﬁnd-
ings and underlying metabolic changes do not allow fracture risk to be
derived from T-Scores analogous to osteoporosis testing. Osteomalacia
in HPP can also confound interpretation of DXA results with normal or
slightly osteopenic results. Further, normal DXA results do not ne-
cessarily rule out bone disease or risk of fracture. Although inter-
pretation of DXA ﬁndings in HPP and associated changes during en-
zyme replacement therapy are not yet established, such data are likely
to become available in the future to guide recommendations, for ex-
ample, in terms of dosing of supportive/additional treatment mod-
alities. To screen for changes in scoliosis or development of compres-
sion fractures, height measurements on a calibrated stadiometer are
recommended at every visit.
Assessments of mobility and musculoskeletal function, such as the
6MWT [72], Chair Stand Test [83], and Short Physical Performance
Battery [84], are recommended. Mobility assessments can be video-
taped to allow comparisons over time, although subtle changes may be
diﬃcult to interpret. Evaluation of muscle strength and power is useful
to monitor eﬀects during treatment. Muscle performance can be as-
sessed using function assessments (e.g., Bruininks-Oseretsky Test of
Motor Proﬁciency, Second Edition [BOT-2]) and handheld dynamo-
metry. However, it should be noted that the BOT-2 is validated only for
patients aged 4–21 years [85]. In adult patients, changes in medication
and dosage of analgesics can be monitored to identify possible changes
in pain levels. QOL may be assessed using a questionnaire, such as the
Medical Outcomes Study Short Form-36 health survey [80].
5. Management of perceived treatment failure
The panel recommends additional assessments for identifying a lack
of improvement or treatment failure in patients receiving asfotase alfa.
For infants who do not exhibit skeletal improvement after 3 to 6 months
of treatment (or in children after 6–9 months) or children who stop
Table 6
Monitoring recommendations for adult patients with HPP treated with asfotase alfa.
Assessment Frequency Special considerations
Radiograph Baseline and 1 year; as clinically indicated • Comprehensive skeletal survey at baseline as appropriate• Should be read by a radiologist experienced in recognizing skeletal dysplasias• Detection of pseudo-fractures and insuﬃciency fracturesa
DXA At physician's discretion; at least every 5 years • Initial evaluation of fracture risk beyond HPP• Absolute BMD values to monitor changes over time
MRI As clinically indicated • Early detection of stress and insuﬃciency fractures and bone marrow edema• Joint monitoring
Bone biopsy Baseline and follow-up during treatment if indicated by
bone turnover markers, at the discretion of the clinician
• Particularly in patients with additional skeletal risk factors• Risk of fracture possible at site of biopsy• Needs to collected, processed, and read by team experienced in metabolic bone disorders
Dental Baseline and then routine dental visits • Provide a note to dentist to alert if changes are observed (i.e., premature tooth loss, abnormal
dentition, dental caries, enlarged pulp changers of teeth [77]) or treatment with asfotase alfa
is initiated
Mobility Baseline, 3, 6, and 12 months, and then annually • Not in conjunction with bone biopsy (as pain from biopsy may impact ambulation)• 6MWT [72]
Muscle strength Baseline, 3, 6, and 12 months, and then annually • Dynamometry
Gait Baseline, 3, 6, and 12 months, and then annually • Videotape gait or use GAITRite, if available; otherwise, perform observational gait analysis
Pain Baseline, 3, 6, and 12 months, and then annually • Wong-Baker FACES Pain Rating Scale [78]; 0–10 numeric pain rating scale [79]• Collect use of medications for pain relief, loss of work
QOL Baseline, 6 and 12 months, and then annually • Recommend EQ-5D-5L: well validated, multiple languages, 2 pages/5 questions.• Recommend a scale to follow (e.g., SF-36 [80])
GI As clinically indicated • Emerging natural history data indicates that functional GI disorders or feeding issues may be
present in patients with HPP
• GI consult may be needed
Nutrition Baseline and as clinically indicated • Not necessary for all
Safety See Table 8
6MWT, 6-Minute Walk Test; BMD, bone mineral density; DXA, dual-energy x-ray absorptiometry; EQ-5D-5L, EuroQol 5-dimension 5-level health questionnaire; GI, gastrointestinal; HPP,
hypophosphatasia; MRI, magnetic resonance imaging; QOL, quality of life; SF-36, Medical Outcomes Study Short Form-36 Health Survey.
a An insuﬃciency fracture is caused by normal stress on a weakened bone [81]. Pseudo-fractures are a type of insuﬃciency fracture, which on radiograph, appear as narrow
radiolucent bands composed of poorly mineralized excess osteoid across the cortex [82].
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having improvement in mineralization and/or show recurrence of
symptoms, additional radiographs and laboratory tests, including ALP,
PLP, PTH, calcium, vitamin D, PO4, magnesium, urine calcium/creati-
nine ratio, can be performed. Immunoglobulin G (IgG) anti–asfotase
alfa antibody testing is not currently commercially available; it is
available for research use only and through the HPP Registry (www.
hppregistry.com). Weight and length/height in infants and children
should increase steadily and progress along percentile lines during
treatment with asfotase alfa. If growth is not observed, inadequate
nutrition or development of musculoskeletal conditions, such as sco-
liosis, should be considered. Similarly, the lack of an increase in head
circumference should prompt further investigation of possible cranio-
synostosis. It is also important to assess the role of antibodies and
compliance in a patient with perceived treatment failure. Based on the
ﬁndings and discussion with the patient, parent, or caregiver, the
physician can consider adjusting the dose according to the prescribing
information.
6. Safety monitoring
6.1. Injection site reactions (ISRs)
The most common adverse events (AEs) in patients treated with
asfotase alfa are ISRs, occurring in approximately 73% of patients in
clinical studies [40]. ISRs include injection site erythema, discoloration,
pain, pruritus, swelling, induration, macule, bruising, and nodules,
among others [37]. Fig. 2 shows images of typical ISRs after sub-
cutaneous injections of asfotase alfa.
Clinicians should ensure that patients, parents, and caregivers are
educated regarding proper injection technique before allowing in-
dependent administration. Asfotase alfa is dosed based on weight and is
available in multiple diﬀerent strength vials. Clinicians should refer to
the prescribing information for appropriate guidance on vial conﬁg-
uration for the weight and dose for the patient [37,40,86–88]. The
80 mg/0.8 mL vial of asfotase alfa is not recommended in the United
States for pediatric patients weighing< 40 kg because the systemic
exposure of asfotase alfa achieved is lower than that achieved with the
other strength vials [37]. Basic guidance on proper injection technique
is also available in the prescribing information [37,40,86–88]. Table 7
summarizes recommendations for administration of asfotase alfa based
on guidance in the prescribing information [37,40] and the combined
opinion of the panel of physicians and nurses. Vials of asfotase alfa must
be refrigerated (2–8 °C), but equilibrating the vial to room temperature
by removing from refrigeration ≥15 min before injection may reduce
risk of ISRs. The drug must be administered within 1 hour after removal
from refrigeration [37]. A larger bore needle (e.g., 21–27 gauge) is
recommended for drawing up the dose but should be changed to a
smaller bore needle for administration (e.g., 29–31 gauge), with a
length suﬃcient to penetrate the dermal space. Injection sites should be
rotated among the abdominal area, thigh, and deltoid areas to reduce
risk of lipohypertrophy and injection site atrophy (use of a rotation
scheme can help ensure consistent rotation). Areas that are hot, red-
dened, inﬂamed, thickened, hardened, or swollen should not be in-
jected until these resolve. Antihistamines or acetaminophen may be
taken to manage ISRs. There may be fewer ISRs with administration 3
rather than 6 times per week, although less frequent administration will
require injection of a larger volume. For dose volumes> 1 mL, the
injection volume should be split equally between 2 syringes and 2 in-
jection sites [37].
Initial follow-up should be conducted within 2 weeks of treatment
initiation to obtain information on AEs, including ISRs, medication
storage, and patient concerns about the injection. In addition, patients
can be asked to keep a log of any AEs, including ISRs, and clinicians
should ask questions about AEs at every clinic visit to better understand
patient concerns. This will also allow for education of patients, parents,
and caregivers on appropriate injection technique and the importance
of continuous routine monitoring.
ISRs should be treated empirically, depending on the severity of the
reaction. Some recommendations for management of ISRs are included
in Table 8; these recommendations may change as nurses and physi-
cians gain experience with the administration of asfotase alfa in the
clinical setting.
6.2. Hypersensitivity reactions
Hypersensitivity reactions, including signs and symptoms consistent
with anaphylaxis, have been reported in patients receiving asfotase alfa.
These include diﬃculty breathing, nausea, periorbital edema, dizziness,
Fig. 2. Images of typical injection site reactions ob-
served after subcutaneous administration of asfotase
alfa: (A) transient erythema with warmth and nodules;
(B) erythematous reaction occurring in the ﬁrst
months of injections that later disappeared (note that
erythematous reactions can occur quickly, even after
the ﬁrst injection); (C) purple discoloration at the in-
jection site that typically appears later and is persis-
tent; (D) abdominal lipohypertrophy after 4 years of
treatment. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the
web version of this article.)
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vomiting, fever, headache, ﬂushing, irritability, chills, skin erythema,
rash, pruritus, and oral hypoesthesia. Reactions have occurred within
minutes after subcutaneous administration of asfotase alfa and can
occur for the ﬁrst time in patients who have received treatment for>
1 year [37]. If these reactions occur, immediate discontinuation of
asfotase alfa is recommended and appropriate medical treatment
should be initiated after current medical standards for emergency
treatment. Clinicians need to maintain an index of suspicion for hy-
persensitivity or anaphylactic reactions. Rechallenge of patients who
have experienced hypersensitivity reactions should be done in a clinical
setting where they can be adequately observed. Not all patients may
need to be prescribed self-injectable epinephrine; however, the panel
recommends a prescription for those who have previously experienced
any systemic hypersensitivity reaction beyond an ISR or based on the
physician's judgment. Additionally, based on experience with other
enzyme replacement therapies, panel members recommend that ad-
ministration of asfotase alfa not be scheduled on the same day as a
vaccination or if the patient has a fever of> 103 °F. Measurement of
immunoglobulin E, tryptase, and complement levels may also be useful
after hypersensitivity reactions.
6.3. Additional safety assessments
AEs observed in clinical studies of asfotase alfa were usually of mild
to moderate intensity, were usually not attributed to the drug, and were
consistent with manifestations of HPP [37,90]. Regardless of asfotase
alfa treatment, patients with HPP are at increased risk for developing
ectopic calciﬁcations [37]. Calciﬁcations of the eye (cornea and con-
junctiva) and kidneys were reported in clinical trials of asfotase alfa; no
visual changes or changes in renal function associated with the calci-
ﬁcations were reported. Cases of ectopic calciﬁcation after initiation of
treatment with asfotase alfa were noted to be self-limiting. In some
cases, evidence was insuﬃcient to determine whether events were
consistent with the disease or a result of treatment [37]. Craniosynos-
tosis (associated with increased intracranial pressure), including wor-
sening of pre-existing craniosynostosis, was reported in 4 of 10 patients
in a clinical study of asfotase alfa in HPP patients aged< 3 years [38],
although whether this is associated with underlying disease progression
has not been elucidated.
Panel recommendations for monitoring and management of AEs are
summarized in Table 8. Consistent with prescribing information
[37,40], advisory panel members recommend ophthalmologic ex-
aminations and renal ultrasounds be performed at baseline and peri-
odically during treatment to monitor for signs and symptoms of ectopic
calciﬁcations and changes in vision and renal function. Periodic mon-
itoring for craniosynostosis, including fundoscopy for signs of papille-
dema, and prompt intervention for increased intracranial pressure are
recommended for patients aged< 5 years. For perinatal and infantile
patients, the panel recommends that an ophthalmologist follow-up
every 3 months for the ﬁrst year and every 6 months thereafter to
monitor for increased intracranial pressure and ectopic eye calciﬁca-
tions in addition to clinical monitoring. The panel also advises that
adult patients at increased cardiovascular risk be monitored for vas-
cular calciﬁcations per standard guidelines [91].
Calcium restriction is often recommended in infants/children with
HPP to manage hypercalcemia. Once treatment with asfotase alfa has
been initiated, restrictions may be lifted and supplementation with
additional calcium may be required to maintain PTH within the normal
range [13,38,40] (Table 8). As such, serum calcium, phosphorous, vi-
tamin D, and PTH levels should be monitored very closely after in-
itiating asfotase alfa in these patients (as described in Table 3). In
perinatal and infantile patients, ionized calcium should be measured; if
ionized calcium testing is not available, albumin levels are needed to
interpret calcium ﬁndings.
Across 5 clinical studies, eﬃcacy was not reduced even though
antidrug antibodies were detected [40]. Anti–asfotase alfa antibody
measurement may be considered a goal for patients currently on com-
mercial treatment; however, it is not currently available commercially
in the clinical setting. Anti–asfotase alfa antibody measurement is
available for research use only and through the HPP Registry. Inter-
pretation of results and impact on patient management remains to be
determined.
7. Discussion
HPP is a systemic, metabolic disease with onset of signs and
symptoms ranging from in utero to adulthood and a variety of clinical
features and complications [1,2,13,26]. Enzyme replacement therapy
with asfotase alfa is an approved treatment for patients with HPP
[37,90]. The primary goal of treatment, to treat bone manifestations of
the disease, extends to goals related to the sequelae of bone manifes-
tations, which range from improved growth and mobility to improved
Table 7
Recommendations for administration of asfotase alfa [37,40].
Technique Recommendation
Preinjection preparation • Allow asfotase alfa to reach room temperature before injecting (remove from refrigeration ≥ 15 min before injection) [37]• Inject within 1 hour of removal from refrigeration [37,40]• Use good sterile technique (wipe site with alcohol wipe before injecting; always use a new syringe and needle) [37]• Skin prep: ethylene glycol or lidocaine spray may reduce stinging• Pinch skin before injection
Syringe use/injection • Use a large-gauge needle (e.g., 21–27 gauge) to pull medication from the vial• Change to a small-gauge needle (e.g., 29–31 gauge) to administer
Injection technique • Always inject into the subcutaneous tissue and not the skin• Inject at 45- or 90-degree angle (45-degree angle for patients with little fat)• Asfotase alfa can be injected into 3 places in the body: abdominal area, thigh, or deltoid [37]
– Abdomen: always inject ≥2 in. away from the umbilical cord
– Thighs: use the front or outer aspects of both thighs ≥4 in. above the knees AND 4 in. below the uppermost part of the thighs; avoid the inner
aspect of the thighs at all costs
– Upper or outer aspects of both upper arms: may be more diﬃcult to inject here as there may not be enough subcutaneous tissue to enable a good
pinch
Frequency of injection • Administering asfotase alfa 2 mg/kg 3 times per week may help reduce the frequency of ISRs compared with administration 6 times per week• Split larger volume (> 1 mL) into 2 syringes for 2 injections at separate sites [37,40]
Site rotation • Do not administer injections in areas that are hot, reddened, inﬂamed, thickened, hardened, or swollen [37]• Rotate injection sites [37,40]; use a rotation scheme to ensure consistency in rotation• Always keep a log to ensure that you are keeping track of your rotation schedule• Inject into diﬀerent spots even in the same quadrant to avoid injecting into the exact same spot (using a stencil might help)
ISRs, injection site reactions.
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ventilatory status, to survival, among others (Table 2). The current
consensus recommendations provide a basic framework for monitoring
patients with HPP for whom the decision to treat has been made.
However, the treatment and monitoring of patients with HPP should be
tailored to the patient based on the individual's medical history and
clinical manifestations and may vary from country to country.
Several unmet needs remain in the assessment of patients with HPP
who are receiving asfotase alfa. For example, standardized, commer-
cially available assays for PPi, direct measurement of PLP, and
immunogenicity on treatment will have clinical utility in the overall
management of HPP. In addition, a HPP-speciﬁc tool is needed to assess
QOL. Given accumulating data on asfotase alfa and HPP, guidance of-
fered in this consensus report will continue to evolve.
An HPP Registry (www.hppregistry.com) has been established to
better understand both the natural history of HPP and to monitor and
evaluate long-term treatment eﬀects of asfotase alfa. Patients and their
caregivers should be encouraged to contribute their data to the registry.
Table 8
Recommendations for monitoring and management of adverse events in patients with HPP treated with asfotase alfa.
Adverse event Description Monitoring/management recommendations
Hypersensitivity reactions • Signs and symptoms consistent with anaphylaxis, including
diﬃculty breathing, choking sensation, nausea, periorbital edema,
and dizziness, have occurred within minutes after subcutaneous
administration of asfotase alfa and can occur in patients on
treatment for> 1 year
• Other hypersensitivity reactions have been reported, including
vomiting, fever, headache, ﬂushing, irritability, chills, skin
erythema, rash, pruritus, and oral hypoesthesia
• Educate/discuss at every visit• Avoid injection if fever or anesthesia on same day• Do not schedule vaccinations on same day as injection (may require
missing dose if patient is receiving asfotase alfa daily)
• If a severe hypersensitivity reaction occurs, discontinue asfotase alfa
and consider initiating appropriate medical treatment including:
– Administer epinephrine
– Administer antihistamine
– Administer IV corticosteroids
– Manage ﬂuid volume/hypotension with IV ﬂuids
– For respiratory symptoms, administer a β-agonist (e.g., albuterol) via
metered-dose inhaler or nebulizer
– For signiﬁcant dyspnea, cyanosis, or wheezing, administer moderate-
to high-ﬂow oxygen by nasal cannula or mask
– Initiate advanced CPR, if necessary
• Consider the risks and beneﬁts of readministering asfotase alfa after a
severe reaction; if decision is made to readminister, monitor patients for
a reoccurrence of signs and symptoms of a severe hypersensitivity
reaction and ensure access to epinephrine or other appropriate
prescribed medication
ISRs • Local ISRs including erythema, rash, discoloration, pruritus, pain,
papule, nodule, and atrophy
• These have been generally assessed as nonserious, mild to moderate
in severity, and self-limiting
• Monitor at each clinical assessment• Advise patients to follow proper injection technique and to rotate
injection sites
• Ask patients to keep a diary to record ISRs• For mild to moderate events or recurrent mild events, the following is
recommended (can be administered 1 hour before injection):
– Antihistamine (diphenhydramine, hydroxyzine, or chlorpheniramine)
plus acetaminophen or ibuprofen
• Include dermatologist evaluation if indicated• Administration of asfotase alfa should be interrupted in any patient
experiencing severe injection reactions, and appropriate medical
therapy should be administered [40]
Lipodystrophy • Localized lipodystrophy, including lipoatrophy and
lipohypertrophy, has been reported at injection sites after several
months in patients treated with asfotase alfa in clinical studies
• Monitor at each clinical assessment• Advise patients to follow proper injection technique and to rotate
injection sites
Hypercalcemia and
hypocalcemia
• Although calcium restriction is often recommended in patients with
HPP to manage hypercalcemia, once asfotase alfa has been initiated,
restrictions may be reversed and supplementation may be required
to maintain PTH within normal range [13,38,40]
• Monitor serum PTH, calcium, phosphorous, and 25(OH)D
concentrations as needed in acute hypercalcemia until controlled
• Calcium levels should be monitored very closely after initiating asfotase
alfa in perinatal/infantile patients
• Calcium and vitamin D supplementation may be needed during
treatment
Craniosynostosis • Can lead to increased intracranial pressure• In clinical studies of asfotase alfa, craniosynostosis (including
worsening of pre-existing craniosynostosis) was reported in HPP
patients age< 5 years
• There are insuﬃcient data to establish a causal relationship
between exposure to asfotase alfa and progression of
craniosynostosis
• Monitor at baseline, every 3 months for the ﬁrst year, and then every
6 months for patients age< 3 years and annually for patients
age> 3 years, depending on clinical need
• Monitor for cranial deformation, premature closing fontanel, bulging,
edema, calciﬁcation, head circumference
• Ophthalmic examination (fundoscopy for signs of papilledema)• Neurologic examination• Cranial CT as clinically indicated if craniosynostosis is suspected• Prompt intervention for increased intracranial pressure in patients
age< 5 years [40]
Ectopic eye calciﬁcation • Ophthalmic (conjunctival and corneal) calciﬁcation has been
reported in patients with HPP in clinical studies of asfotase alfa [40]
• There are insuﬃcient data to establish a causal relationship
between exposure to asfotase alfa and ectopic eye calciﬁcations
• Ophthalmic examination at baseline and every 1 year or as clinically
indicated
Nephrocalcinosis • Nephrocalcinosis has been reported in patients with HPP in clinical
studies of asfotase alfa [89]
• There are insuﬃcient data to establish a causal relationship
between exposure to asfotase alfa and nephrocalcinosis
• Renal ultrasound and urinary Ca/Cr at baseline and every 6 months,
as clinically indicated
• Monitor during acute phase until stable• Assess at baseline and every 3 months in perinatal/infantile patients and
at baseline, 6 months, and then annually in children and adults
Ca/Cr, calcium/creatinine ratio; CPR, cardiopulmonary resuscitation; CT, computed tomography; HPP, hypophosphatasia; ISR, injection site reaction; OHD, 25-hydroxyvitamin D; IV,
intravenous; PTH, parathyroid hormone.
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8. Conclusions
Because of the systemic manifestations of HPP, a coordinated,
multidisciplinary, team-based and patient-focused approach is needed
for managing patients receiving asfotase alfa therapy. These consensus
recommendations are based on the expert opinion of physicians ex-
perienced in the management of HPP and are intended to serve as a
basic framework for monitoring patients with HPP for whom the de-
cision to treat has been made. However, monitoring assessments must
be tailored to the individual patient, depending on medical history,
speciﬁc clinical manifestations, and the clinician's professional judg-
ment. Clinicians are reminded that the recommendations provided may
evolve as more scientiﬁc information becomes available.
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